Thalidomide for Unresectable Hepatocellular Cancer With Optional Interferon Alpha-2a Upon Disease Progression
I. Determine the feasibility and activity of thalidomide in patients with unresectable
II. Evaluate the toxicity of thalidomide in these patients. III. Assess the use of
interferon alfa in patients who develop disease progression while being treated with
OUTLINE: This is a multicenter study.
Patients receive oral thalidomide once daily. Patients on a stable dose of thalidomide for
at least 4 weeks with evidence of progressive disease receive interferon alfa subcutaneously
twice daily. Treatment continues in the absence of disease progression after initiation of
interferon alfa therapy or unacceptable toxicity.
Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Matthew D. Volm, MD
New York University School of Medicine
United States: Food and Drug Administration
|Mount Sinai School of Medicine||New York, New York 10029|
|NYU School of Medicine's Kaplan Comprehensive Cancer Center||New York, New York 10016|